Patents by Inventor Chris Dealwis

Chris Dealwis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20220249457
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of an oxadiazole, thiazole, diazole, triazole, or tetrazole ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 11, 2022
    Inventors: Chris DEALWIS, Hsueh-Yun LEE, Rajesh VISWANATHAN, Sarah HUFF
  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20210299095
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a hydrazone or hydrazine ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: July 18, 2019
    Publication date: September 30, 2021
    Inventor: Chris Dealwis
  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20190054083
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: February 13, 2018
    Publication date: February 21, 2019
    Inventor: Chris Dealwis
  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20180360782
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Inventor: Chris Dealwis
  • Method of modulating ribonucleotide reductase
    Patent number: 9889129
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: February 13, 2018
    Assignee: Case Western Reserve University
    Inventor: Chris Dealwis
  • Pyro-glutamate A? targeting agents
    Patent number: 9109021
    Abstract: A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-A? targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-A? effective to inhibit amyloid beta aggregation in the subject.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: August 18, 2015
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Chris Dealwis
  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20150094314
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: March 21, 2013
    Publication date: April 2, 2015
    Inventor: Chris Dealwis
  • PYRO-GLUTAMATE ABETA TARGETING AGENTS
    Publication number: 20130302326
    Abstract: A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-A? targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-A? effective to inhibit amyloid beta aggregation in the subject.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 14, 2013
    Inventor: Chris Dealwis
  • Pyro-glutamate A? targeting agents
    Patent number: 8512677
    Abstract: A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-A? targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-A? effective to inhibit amyloid beta aggregation in the subject.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: August 20, 2013
    Assignee: Case Western Reserve University
    Inventor: Chris Dealwis
  • PYRO-GLUTAMATE A BETA TARGETING AGENTS
    Publication number: 20120045392
    Abstract: A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-A? targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-A? effective to inhibit amyloid beta aggregation in the subject.
    Type: Application
    Filed: April 27, 2010
    Publication date: February 23, 2012
    Inventor: Chris Dealwis